No correlation between COMT genotype and entacapone benefits in Parkinson's disease

Ji Seon Kim, Ji Young Kim, Jong Min Kim, Jae Woo Kim, Sun Ju Chung, Sung Reul Kim, Mi J. Kim, Hee Tae Kim, Kyoung Gyu Choi, Dong Ick Shin, Young Hee Sung, Kwang Soo Lee, Han Joon Kim, Jinwhan Cho, Mee Young Park, Hyun Young Park, Seong Min Choi, Kun Woo Park, Ho Won Lee, Tae Beom Ahn & 3 others Oh Dae Kwon, Sang Jin Kim, Beom S. Jeon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily "off" duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily "on" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased "on" duration and improved motor function in all COMT genotypes.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalNeurology Asia
Volume16
Issue number3
Publication statusPublished - 2011 Oct 11

Fingerprint

Catechol O-Methyltransferase
Parkinson Disease
Genotype
Levodopa
Activities of Daily Living
Biological Availability
entacapone
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Kim, J. S., Kim, J. Y., Kim, J. M., Kim, J. W., Chung, S. J., Kim, S. R., ... Jeon, B. S. (2011). No correlation between COMT genotype and entacapone benefits in Parkinson's disease. Neurology Asia, 16(3), 211-216.

No correlation between COMT genotype and entacapone benefits in Parkinson's disease. / Kim, Ji Seon; Kim, Ji Young; Kim, Jong Min; Kim, Jae Woo; Chung, Sun Ju; Kim, Sung Reul; Kim, Mi J.; Kim, Hee Tae; Choi, Kyoung Gyu; Shin, Dong Ick; Sung, Young Hee; Lee, Kwang Soo; Kim, Han Joon; Cho, Jinwhan; Park, Mee Young; Park, Hyun Young; Choi, Seong Min; Park, Kun Woo; Lee, Ho Won; Ahn, Tae Beom; Kwon, Oh Dae; Kim, Sang Jin; Jeon, Beom S.

In: Neurology Asia, Vol. 16, No. 3, 11.10.2011, p. 211-216.

Research output: Contribution to journalArticle

Kim, JS, Kim, JY, Kim, JM, Kim, JW, Chung, SJ, Kim, SR, Kim, MJ, Kim, HT, Choi, KG, Shin, DI, Sung, YH, Lee, KS, Kim, HJ, Cho, J, Park, MY, Park, HY, Choi, SM, Park, KW, Lee, HW, Ahn, TB, Kwon, OD, Kim, SJ & Jeon, BS 2011, 'No correlation between COMT genotype and entacapone benefits in Parkinson's disease', Neurology Asia, vol. 16, no. 3, pp. 211-216.
Kim JS, Kim JY, Kim JM, Kim JW, Chung SJ, Kim SR et al. No correlation between COMT genotype and entacapone benefits in Parkinson's disease. Neurology Asia. 2011 Oct 11;16(3):211-216.
Kim, Ji Seon ; Kim, Ji Young ; Kim, Jong Min ; Kim, Jae Woo ; Chung, Sun Ju ; Kim, Sung Reul ; Kim, Mi J. ; Kim, Hee Tae ; Choi, Kyoung Gyu ; Shin, Dong Ick ; Sung, Young Hee ; Lee, Kwang Soo ; Kim, Han Joon ; Cho, Jinwhan ; Park, Mee Young ; Park, Hyun Young ; Choi, Seong Min ; Park, Kun Woo ; Lee, Ho Won ; Ahn, Tae Beom ; Kwon, Oh Dae ; Kim, Sang Jin ; Jeon, Beom S. / No correlation between COMT genotype and entacapone benefits in Parkinson's disease. In: Neurology Asia. 2011 ; Vol. 16, No. 3. pp. 211-216.
@article{67e75d7b50de46ff8404a52682ea86ea,
title = "No correlation between COMT genotype and entacapone benefits in Parkinson's disease",
abstract = "Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily {"}off{"} duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily {"}on{"} duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3{\%}) had the low-activity COMT genotype, 68 patients (40.5{\%}) had the intermediate-activity COMT genotype, and 81patients (48.2{\%}) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased {"}on{"} duration and improved motor function in all COMT genotypes.",
author = "Kim, {Ji Seon} and Kim, {Ji Young} and Kim, {Jong Min} and Kim, {Jae Woo} and Chung, {Sun Ju} and Kim, {Sung Reul} and Kim, {Mi J.} and Kim, {Hee Tae} and Choi, {Kyoung Gyu} and Shin, {Dong Ick} and Sung, {Young Hee} and Lee, {Kwang Soo} and Kim, {Han Joon} and Jinwhan Cho and Park, {Mee Young} and Park, {Hyun Young} and Choi, {Seong Min} and Park, {Kun Woo} and Lee, {Ho Won} and Ahn, {Tae Beom} and Kwon, {Oh Dae} and Kim, {Sang Jin} and Jeon, {Beom S.}",
year = "2011",
month = "10",
day = "11",
language = "English",
volume = "16",
pages = "211--216",
journal = "Neurology Asia",
issn = "1823-6138",
publisher = "ASEAN Neurological Association",
number = "3",

}

TY - JOUR

T1 - No correlation between COMT genotype and entacapone benefits in Parkinson's disease

AU - Kim, Ji Seon

AU - Kim, Ji Young

AU - Kim, Jong Min

AU - Kim, Jae Woo

AU - Chung, Sun Ju

AU - Kim, Sung Reul

AU - Kim, Mi J.

AU - Kim, Hee Tae

AU - Choi, Kyoung Gyu

AU - Shin, Dong Ick

AU - Sung, Young Hee

AU - Lee, Kwang Soo

AU - Kim, Han Joon

AU - Cho, Jinwhan

AU - Park, Mee Young

AU - Park, Hyun Young

AU - Choi, Seong Min

AU - Park, Kun Woo

AU - Lee, Ho Won

AU - Ahn, Tae Beom

AU - Kwon, Oh Dae

AU - Kim, Sang Jin

AU - Jeon, Beom S.

PY - 2011/10/11

Y1 - 2011/10/11

N2 - Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily "off" duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily "on" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased "on" duration and improved motor function in all COMT genotypes.

AB - Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily "off" duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily "on" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased "on" duration and improved motor function in all COMT genotypes.

UR - http://www.scopus.com/inward/record.url?scp=80053467017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053467017&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 211

EP - 216

JO - Neurology Asia

JF - Neurology Asia

SN - 1823-6138

IS - 3

ER -